Abstract Precision medicine in hepatocellular carcinoma (HCC) relies on validated biomarkers that help subgroup patients for targeted treatment. Here. we identified a novel candidate oncogene. ribosomal protein L22-like1 (RPL22L1). https://danddcollectiblers.shop/product-category/specialty-chocolate/